Postoperative Effects of Propofol Versus Sevoflurane Anesthesia

Postoperative Effects of Propofol Versus Sevoflurane Anesthesia During Elective Non-Cardiac Surgeries. A Randomized Clinical Trial

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05935930

Enrollment

Registered

2023-07-07

Start date

2021-12-01

Completion date

2024-12-15

Last updated

2025-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General Anesthetic Drug Adverse Reaction

Keywords

Cognitive function, General anesthesia, Inflammatory response, Oxidative stress, Propofol, Sevoflurane

Brief summary

Background: The choice of appropriate anesthetics is essential to protect brain function, decrease perioperative complications, and provide high-quality care, and better quality of life. Objectives: To compare the efficacy and safety of propofol versus sevoflurane in patients undergoing elective, non-cardiac operations under general anesthesia. Methods: This was a randomized (1:1), parallel, phase four clinical trial; carried out on 44 patients, who were candidates for elective, non-cardiac operations under general anesthesia at our hospital. Patients were randomly allocated into two equal groups in which anesthesia was maintained with propofol infusion in group P and sevoflurane inhalation in group S.

Interventions

DRUGPropofol 10 MG/ML Injection

Propofol infusion

DRUGSevoflurane Inhalation Liquid

Sevoflurane inhalation

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* American Society of Anesthesiologists (ASA) physical status ≤ II * Age from 21 years * Body Mass Index (BMI) 25-35 kg/m2

Exclusion criteria

* ASA physical status \> II * Age \< 21 years * Patients with Montreal Objective Cognitive Assessment (MoCA-B) score \< 24 points * Patients with significant cardiovascular, cerebrovascular, respiratory, liver, renal, endocrine, blood, or immune diseases * Patients with visual or auditory disease, infection, chronic inflammation, disturbance of consciousness, cognitive impairment, or dementia * Patients on long-term use of sedatives or steroids, alcohol or drug abuse * Allergy to any of the study drugs

Design outcomes

Primary

Measure	Time frame	Description
Mean and Standard deviation of Neuron Specific Enolase enzyme (µg/L) in blood serum (mean±SD)	24 hours after the end of operation	Before operation (T0), 1 hour after the end of operation (T1), 24 hours the end of operation (T2)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026